-
-
-
-
-
-
-
Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results
-
-
-
-
-
-
-
Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso™ (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025
-
-
-
-
-
-
-
Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025
-
-
-
-
-
-
-
Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma
-
-
-
-
-
-
-
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance
-
-
-
-
-
-
-
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance
-
-
-
-
-
-
-
Jazz Pharmaceuticals Announces Second Quarter 2023 Financial Results and Raises 2023 Full Year Financial Guidance
-
1,192,288 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

